

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT ON JOINT DEVELOPMENT OF NEW DRUG

This is a voluntary announcement made by Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that KLT-1101, a new biological drug that was jointly developed by the Group and its customer, Kanglilai Pharmaceutical Co., Ltd.* (康立泰藥業有限公司) (“**Kanglilai**”), and categorized under National Class I New Drugs (the “**Joint Development Project on New Drug**”), obtained an encouraging achievement. Kanglilai was established in 2011 and has been devoting itself in the research and development on KLT-1101 in the complete recovery of hemogram and tumor immunotherapy since its establishment.

Under the Joint Development Project on New Drug, the Company accepted the engagement by Kanglilai for the preclinical drug development of KLT-1101. The Board is pleased to announce that the Company has been notified by Kanglilai that the Joint Development Project on New Drug had obtained an encouraging achievement and the application for clinical trial on KLT-1101 was accepted by China Food and Drug Administration (國家食品藥品監督管理局) (the “**CFDA**”) on 4 May 2017. The clinical trial will be duly commenced upon further review and approval of the CFDA.

KLT-1101 is a kind of recombinant human cytokine proteins, which demonstrates positive signs of treatment effects in the complete recovery of hemogram, suppression of tumor cell proliferation, improvement in immunity of patients, etc. Subject to the further approval of CFDA after the completion of the clinical trial and launching the drug to the market, KLT-1101 can ameliorate the negative situation of patients' inability to complete their treatment cycle or even mortality caused by weakened blood production due to chemoradiotherapy. Meanwhile, the drug could efficiently prevent, relieve and treat radiation damage to the human body. It is believed that KLT-1101 could also serve as a backup drug for nuclear emergency and help enhance the national standard of responsive measures on the prevention of nuclear emergency.

The Group believes that the encouraging achievement of the Joint Development Project on New Drug demonstrates the technological strengths of the Group in preclinical drug research and development.

By order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman and Chief Executive Officer

Hong Kong, 29 May 2017

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

* *For identification purposes only*